The Pcos Diagnostic Market is estimated to be valued at US$ 3.53 Bn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:-
The Pcos Diagnostic Market encompasses diagnostic methods such as menstrual irregularity assessment, hormonal testing, imaging, and pelvic ultrasound for detecting polycystic ovary syndrome (PCOS) among women. PCOS is one of the most common endocrine disorders among women of reproductive age that causes enlarged ovaries with small cysts on the outer edges. Non-invasive screening methods such as at-home ovulation and fertility tests, as well as blood-based biomarker screening are gaining popularity due to their convenience and minimal risks involved.
Market Dynamics:-
The growth of the Pcos Diagnostic Market is driven by the adoption of non-invasive screening solutions and growing public awareness about PCOS. Non-invasive screening methods such as at-home urine or blood-based LH tests enable real-time monitoring of ovulation and fertility without undergoing clinical procedures. They provide discreet tracking of reproductive health that empowers women to take preventive actions. Another major driver is the rising campaign by healthcare agencies to spread knowledge about PCOS symptoms and risks of long-term complications. According to the America College of Obstetricians and Gynecologists, PCOS remains under-diagnosed primarily due to the lack of disease awareness among at-risk women and physicians. Promoting early detection can aid timely clinical management and reduce adverse outcomes.
Segment Analysis:-
The Pcos diagnostic market is segmented into endocrine tests (Blood tests and Saliva tests), ovarian testing (Ultrasound), and genetic testing. The endocrine tests sub-segment accounts for the largest market share owing to high preference of blood and saliva tests for initial diagnosis of pcos. Blood tests measure hormone levels like LH, FSH, testosterone, Anti-Mullerian hormone (AMH), and insulin which help determine pcos.
PEST Analysis:-

• Political: Regulations regarding women's health issues and awareness programs by governments boost the market.
• Economic: Rising income levels increase affordability of diagnosis.
• Social: Increasing awareness among women about pcos and related health issues drives the market.
• Technological: Advancements in diagnostic equipments and kits improve accuracy and efficiency of tests. Development of home testing kits widens access.

Key Takeaways:-
The Global Pcos Diagnostic Market Growth is expected to witness high, exhibiting CAGR of 5.0% over the forecast period, due to increasing awareness about women's health issues. North America dominates the market due to presence of major players, advanced healthcare facilities and increasing obese population vulnerable to pcos.
The global Pcos diagnostic market size for 2023 is estimated at US$ 3.53 Bn. The United States accounts for the largest market share in the North America region owing to higher accessibility to diagnostic facilities and adoption of advanced devices for diagnosis.
Key players operating in the Pcos diagnostic market are Roche Diagnostics, Abbott Laboratories, Quest Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Bio-Rad Laboratories, Agilent Technologies, Hologic, F. Hoffmann-La Roche Ltd., IGENOMIX, Myriad Genetics, Ansh Labs, Diagnostica Stago, Beckman Coulter, and Randox Laboratories Ltd. Major players are focusing on partnerships, new product launches and geographical expansions to strengthen their market presence.
 
Read More - 
https://www.newsstatix.com/pcos-diagnostic-market-size-and-trends-analysis/